Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

410
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
410
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

594
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
594
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

312
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
312
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

72
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
72
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

413
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
413

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing quantitative clinical pharmacology competencies in Francophone Africa through an on-line learning framework.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

Psychotropic drug-induced weight gain and untargeted metabolomics: machine learning-driven results from a prospective cohort study.

Translational psychiatry·2026
Same author

Late-life difficult-to-treat depression and dementia subtypes: a naturalistic cohort study using electronic health records.

Frontiers in psychiatry·2026
Same author

Neural signatures of major depression across the episodic memory circuitry.

Journal of affective disorders·2026
Same author

Differential Factor-Level MADRS Response Associated With Seizure Duration in Electroconvulsive Therapy: Exploratory Findings.

The journal of ECT·2026
Same author

Adverse childhood experiences and care-seeking for depression: evidence from a population-based cohort.

Journal of affective disorders·2026
Same journal

Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin.

Basic & clinical pharmacology & toxicology·2026
Same journal

Identifying Current Needs in Paediatric Pharmacoepidemiology: Insights From the NorPEN 2025 Workshop.

Basic & clinical pharmacology & toxicology·2026
Same journal

Contribution of Countries and International Collaboration in Clinical Pharmacology Research. A Cross-Sectional Bibliometric Study of Six Top Ranked Specialty Society Journals.

Basic & clinical pharmacology & toxicology·2026
Same journal

Pharmacological Inhibition of Cav2.2 Channels by Recombinant Phα1β Toxin (CTK01512-2).

Basic & clinical pharmacology & toxicology·2026
Same journal

Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease.

Basic & clinical pharmacology & toxicology·2026
Same journal

Modulation of Respiratory Diseases by the Endocannabinoid System: A Therapeutic Perspective.

Basic & clinical pharmacology & toxicology·2026
See all related articles

Related Experiment Video

Updated: Nov 12, 2025

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

1.8K

Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric

Aurélie Delacrétaz1,2, Anaïs Glatard1, Céline Dubath1

  • 1Department of Psychiatry, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.

Basic & Clinical Pharmacology & Toxicology
|March 18, 2021
PubMed
Summary
This summary is machine-generated.

Valproate treatment significantly increased body mass and decreased HDL cholesterol in psychiatric patients within one month. Monitoring metabolic health is crucial for patients starting valproate.

Keywords:
anticonvulsantsdyslipidaemiaepilepsiaobesitypsychopharmacology

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.5K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K

Related Experiment Videos

Last Updated: Nov 12, 2025

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

1.8K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.5K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K

Area of Science:

  • Psychiatry and Pharmacology
  • Metabolic Medicine

Background:

  • Valproate's impact on lipid profiles in psychiatric patients is understudied.
  • Aripiprazole serves as a control due to its low metabolic risk.

Purpose of the Study:

  • To compare metabolic parameter changes in psychiatric patients initiating valproate versus aripiprazole.
  • To assess early-stage (first month) metabolic effects of valproate.

Main Methods:

  • Observational, prospective study comparing 39 patients on valproate with 39 on aripiprazole.
  • Monitoring of body mass index and HDL-C levels during the first year of treatment.

Main Results:

  • Valproate significantly increased BMI (24.8 to 25.2 kg/m²) and decreased HDL-C (1.39 to 1.27 mmol/L) within one month (P=.03 and P=.02).
  • 54% of valproate patients experienced early HDL-C decrease (≥5%) versus 15% on aripiprazole (P<.001).
  • Metabolic parameters remained stable in the aripiprazole group.

Conclusions:

  • Valproate initiation is associated with early adverse metabolic changes, particularly concerning lipid profiles.
  • Prospective metabolic monitoring is essential for psychiatric patients starting valproate.
  • Further research with larger samples is needed to develop interventions against valproate-induced metabolic effects.